Could a Prostate Cancer Treatment Raise Colon Cancer
WEDNESDAY, Nov. 10 (HealthDay News) -- Men taking hormone
therapy for prostate cancer may have a slightly increased risk of
developing colorectal cancer, a new study suggests.
Androgen deprivation therapy is often prescribed to treat
prostate cancer. But its use in treating low-risk cancer is
controversial, because two potential side effects, diabetes and
obesity, are risk factors for colorectal cancer, the researchers
"We found that the use of androgen deprivation therapy, either through injections or through surgical castration, for prostate cancer was associated with a 30 to 40 percent increase in risk for colorectal cancer," said lead researcher Dr. Vahakn B. Shahinian, an assistant professor of internal medicine at the University of Michigan.
As experts debate whether routine prostate-specific antigen
(PSA) testing causes many men to undergo unneeded treatment for
prostate cancer, this finding appears to add another piece to the
Shahinian noted that the absolute risk of developing colorectal
cancer because of androgen deprivation therapy is very small. "Over
a five-year period, I would say there would be no more than a 2.5
percent absolute risk of developing colorectal cancer," he
However, he thinks androgen deprivation therapy is overused.
Its value in treating late-stage prostate cancer that has
metastasized is well-grounded, Shahinian said. And when combined
with radiation, it is considered beneficial for treating locally
advanced prostate cancer, he added.
But as primary therapy in lower-risk or localized tumors, "I
don't think there is very good evidence for its use," Shahinian
"A lot of men are getting it in settings where they just have a biochemical recurrence of their tumor, so they just have an elevated PSA, but are otherwise doing fine -- that's a scenario where there isn't a proven benefit," he said.
The report is published in the Nov. 10 online edition and the
Dec. 1 print issue of the
Journal of the National Cancer Institute.
Shahinian and colleagues used data from the Surveillance,
Epidemiology, and End Results database of the U.S. National Cancer
The researchers identified 107,859 men aged 67 years or older
diagnosed with prostate cancer between 1993 and 2002, and
followed-up through 2004.
The investigators found a 30 to 40 percent relative increase in
the rate of colorectal cancer among the men who received hormone
therapy compared with those who did not.
The longer the men received hormone therapy, the greater was
their risk of developing colorectal cancer, the researchers found.
The highest risk was seen in men who had their testicles
Jennifer H. Lin, an instructor in preventive medicine at Brigham
and Women's Hospital in Boston and co-author of an accompanying
journal editorial, said this is the first large observational study
showing that androgens may prevent colorectal cancer development in
Earlier research has shown that hormone replacement therapy
lowers the risk for colorectal cancer in postmenopausal women, she
"Obesity is an important risk factor, especially in men, for colorectal cancer development," she added. "Obese men also tend to have lower androgen levels, suggesting a potential role of androgens in colorectal cancer development."
The findings support the need for routine screening for
colorectal cancer and the adoption of lifestyle practices, such as
physical activity, to help prevent colorectal cancer, she said.
"This is especially important among prostate cancer patients who
undergo anti-androgen therapies," Lin stressed.
Dr. Anthony D'Amico, a prostate cancer expert at Brigham and
Women's Hospital, sees the study results differently.
"This is a classic example of true, true and unrelated," he said. Many men diagnosed with prostate cancer get screened for colorectal cancer for the first time, so cancers are picked up because of screening that has nothing to do with treatment, he said.
"To discern if this is a real effect or not, the researchers would have to assess the intervals of colorectal screening in the men who got long-term hormones or prostatectomy or none. I'll bet you'll find that the incidences of this are affected by the fact that most of them are having their screening for the first time," D'Amico said.
"So I am not convinced," he added.
For more information on prostate cancer, visit the
American Cancer Society.
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.